title: Laboratory markers of mast cell and basophil activation in monitoring rush immunotherapy in bee venom-allergic children.
abstract: OBJECTIVE
  To evaluate markers of mast cell and basophil activation in children undergoing the initial phase of honeybee venom immunotherapy (VIT).
  
  
  METHODS
  Five children (four boys and one girl) aged 9.5-18 years with severe systemic bee sting reactions and confirmed IgE-mediated allergy were enrolled. Plasma and urine concentrations of 9α,11β-PGF2 and serum tryptase levels were measured at four time points and peripheral blood basophil count and CD63 expression were measured at three time points in the course of VIT, including 5-day rush initial immunotherapy (cumulative dose of 223 µg of bee venom allergen) and two subsequent maintenance doses of 100 µg.
  
  
  RESULTS
  In the first 40 days of VIT, there was a decrease in mean plasma levels of 9α,11β-PGF2 (from 41.5 to 27.9 pg/ml; p < 0.05), accompanied by an increase in baseline basophil activation (from 2 to 15%; p < 0.05). The median serum tryptase levels increased from 3.45 to 4.40 ng/ml during rush phase and subsequently returned to initial values (statistically not significant). In four patients, the basophil activation test in response to bee venom allergens remained positive throughout the study. The fifth patient was basophil activation test-negative at all three measurements, and a post hoc analysis revealed clinical peculiarities that are discussed in the paper.
  
  
  CONCLUSIONS
  Our preliminary results indicate that plasma levels of 9α,11β-PGF2 decrease while numbers of activated basophils increase during the initial phase of bee venom rush immunotherapy in children.
authors.affiliation: Department of Pediatrics, Polish-American Children's Hospital, Medical Faculty, Jagiellonian University Medical College, Krakow, Poland.
authors.forename: Ewa
authors.initials: E
authors.lastname: Cichocka-Jarosz
authors.forename: Agnieszka
authors.initials: A
authors.lastname: Dorynska
authors.forename: Jacek J
authors.initials: JJ
authors.lastname: Pietrzyk
authors.forename: Radoslaw
authors.initials: R
authors.lastname: Spiewak
mesh_terms: D000293:Adolescent; D001491:Basophils / Q000187:drug effects / Q000276:immunology / Q000378:metabolism* / Q000473:pathology; D001514:Bee Venoms / Q000009:adverse effects; D015415:Biomarkers / Q000097:blood / Q000652:urine; D002452:Cell Count; D015550:Cell Degranulation / Q000187:drug effects; D002648:Child; D003888:Desensitization, Immunologic; D015237:Dinoprost / Q000031:analogs & derivatives / Q000097:blood / Q000652:urine; D005260:Female; D006801:Humans; D006967:Hypersensitivity / Q000175:diagnosis* / Q000188:drug therapy / Q000276:immunology*; D008297:Male; D008407:Mast Cells / Q000473:pathology; D008991:Monitoring, Physiologic / Q000379:methods; D060149:Tetraspanin 30 / Q000096:biosynthesis; D053802:Tryptases / Q000097:blood
chemical_list: D001514:Bee Venoms; D015415:Biomarkers; D060149:Tetraspanin 30; C030320:prostaglandin F2alpha 9-methyl ether; D015237:Dinoprost; D053802:Tryptases